Beth Israel Lahey Health
Beth Israel Deaconess Medical Center

Rolling Out Remdesivir Under EUA

By Julius Yang, MD and Jaime Levash
Beth Israel Deaconess Medical Center

Introduction/Problem

May 1, 2020 the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the emergency use of remdesivir for the treatment of hospitalized patients with severe COVID-19. EUAs are a relatively new pathway that the FDA can utilize when there is a declared health emergency. During the health emergency, things were moving quickly.

Aim/Goal

The goal was to understand the EUA and roll out the medication across the medical center as quickly as possible to help save patients' lives.

The Team

- May Adra, PharmD
- Michael Cocchi, MD
- Mary Ifeoma Eche, PharmD
- David Feinbloom, MD
- Kyle Franko
- Howard Gold, MD
- Margaret Hayes, MD
- John Hrenko, RPh
- Mary LaSaliva, MD
- Jaime Levash
- Christopher McCoy, PharmD
- Ari Moskowitz, MD
- Ameeka Pannu, MD
- Todd Sarge, MD
- Roger Shapiro, MD
- Lauge Sokol-Hessner, MD
- David Sontag
- Conor Stack, MD
- Margaret Stephan, RPh
- Kathryn Stephenson, MD
- Kim Sulmonte, DNP
- Daniel Taupin, MD
- Cheryle Totte, RN
- Julius Yang, MD

The Interventions

- Created three working groups:
  - An Oversight Committee has met to oversee guideline implementation, monitor drug supply, ensure effective communication with staff and patients, and ensure adherence to ethical, regulatory, and patient-centered best practice.
  - A small Interdisciplinary Advisory Workgroup was developed a consensus allocation prioritization guideline based on available evidence and experience regarding treatment of COVID-19 with remdesivir.
  - A Clinical Review Team met daily to review patients potentially eligible for remdesivir EUA allocation per BIDMC guideline, and authorize release from Pharmacy for individual patients.

Results/Progress to Date



83% of patients treated with Remdesivir were discharged home or still in the hospital. Only 17% of patients who agreed to treatment expired.

Lessons Learned

- Create a multidisciplinary team.
- Clear communication to providers explaining the steps to communicate with their patient, order the medication, and documentation needed.
- Administration of remdesivir earlier in illness is more beneficial then later in illness.

Next Steps

The 3 workgroups dismantled. Remdesivir was approved by the FDA in early October 2020 which means no longer a need to complete additional tracking on the amount of medication dispensed, no formal reaction tracking to the FDA, and no prioritization amongst patients since supply was abundant.

For more information, contact:
Jaime Levash, Senior Project Manager Health Care Quality